| Bioactivity | ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC50 values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity[1][1]. |
| Invitro | ZLJ-6 (3, 10, 30 μM, 6 h) 可有效抑制 TNF-α 诱导的单核细胞内皮相互作用和粘附分子 (e-选择素、ICAM-1 和 VCAM-1) 的表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> ZLJ-6 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | ZLJ-6 (3, 10, 30 mg/kg, 口服) 在卡拉胶导的大鼠足跖水肿模型中表现出有效的抗炎活性，在醋酸诱导的小鼠腹腔构建模型中表现出镇痛活性[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 1051931-39-5 |
| Formula | C13H17N3O6S2 |
| Molar Mass | 375.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen L, et al. ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism. Vascul Pharmacol. 2011 Nov-Dec;55(5-6):135-42. [2]. Li L, et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol. 2009 Apr 1;607(1-3):244-50. |